||Purpose: Hepatoma-derived growth factor (HDGF) is a novel growth factor that plays an important role in the pathogenesis and progression of a variety of cancers. The present study was designed to elucidate the role of HDGF expression in breast cancer. |
Patients and Methods: Tissues were collected from patients with breast cancer who underwent surgery. The expression of HDGF, Ki-67, FOXP3, p53, ER, PR and CD4+CD25+ in 71 patients with breast cancer containing a) malignant tissue (n = 58), b) uninvolved breast tissue obtained from tissue distant from the tumor (n = 13) using immunohistochemistry (IHC). The content of CD4+CD25 high in PBMC was determined by flow cytometry. Data were expressed as ROC Curve and the significance of the differences was assessed by ANOVA.
Results: IHC analysis found that the expression level of HDGF and CD4+CD25high in tumor tissues was significantly higher than that in non-tumor tissues (P < 0.001). Besides, HDGF and CD4+CD25high expression was significantly correlated with tumor grades of breast cancer (P < 0.05). Increased circulating HDGF and CD4+CD25high levels were found in serum from patients with breast cancer compared with serum from healthy controls (P < 0.001). The nuclear HDGF labeling index was positively correlated with Ki-67, FOXP3 and p53 in breast cancer (P < 0.05). Finally, incubation with recombinant HDGF significantly increased the content of CD4(+)CD25high T cells in peripheral blood mononuclear cells (PBMCs).
Conclusion: The present study demonstrated HDGF overexpression is correlated with tumor grades, recurrence, proliferation, and tumor immunity in breast cancer. In the future, HDGF may constitute a novel molecular target for diagnosis and treatment of breast cancer.